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Summary The question of whether UK oncologists follow current anthracycline dose modifications when treating patients with liver
dysfunction was addressed through a questionnaire. Oncologists were asked the dose of doxorubicin or epirubicin they would prescribe for a
woman with breast cancer and liver metastases who had one of four different patterns of abnormal liver chemistry. In each case, the median
dose of anthracycline that would have been prescribed was close to that currently recommended. There was, however, wide variation in the
dose that oncologists said they would prescribe, some avoiding an anthracycline altogether, whereas others would give full-dose treatment.
Medical oncologists would prescribe a significantly lower dose of anthracycline than clinical oncologists for a patient with the most severely
disturbed liver tests. Overall, medical oncologists were also significantly more likely to prescribe epirubicin. These results show the need for
new, widely accepted anthracycline dose modifications for patients with liver dysfunction.
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The anthracyclines, doxorubicin and epirubicin, are among the
most widely used cytotoxics in the treatment of adult solid
tumours. These drugs are largely eliminated by hepatic metabo-
lism and biliary excretion. Although dose reductions are recom-
mended forpatients with liver dysfunction (Pharmacia and Upjohn
data sheets), it is not known how widely they have been adopted.
Benjamin et al (1973) first reported increased toxicity in eight
patients with liver metastases treated with full-dose doxorubicin.
This excess toxicity was abrogated in patients with liver dysfunc-
tion treated with a reduced dose of doxorubicin. Subsequently,
Camaggi et al (1982) showed reduced epirubicin clearance in six
patients with liver metastases. These reports led to the current
recommendations for doxorubicin and epirubicin doses based on
serum bilirubin or bromosulphthalein (BSP) clearance. However,
the question of whether liver dysfunction significantly affected
anthracycline clearance remained unclear (de Valeriola, 1994), and
these dose modifications have not been validated. Indeed, there is
no widely accepted definition for liver dysfunction appropriate for
classifying patients with hepatic metastases. The Child-Pugh
criteria (Pugh et al, 1973) have been used, but these reflect severe
hepatic dysfunction or coma and are not applicable in this situa-
tion. Moreover, there are currently no recommendations for
patients receiving anthracyclines by alternative schedules such as
prolonged infusion or weekly administration.
The question of anthracycline dose and liver dysfunction is
important as many patients with the common adult solid tumours,
such as breast cancer, develop liver metastases. Inappropriate treat-
ment may lead to excess toxicity in some patients and suboptimal
treatment for others. The main aim of this study was to identify
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which anthracycline, and at what dose, UK oncologists would
prescribe for a woman with breast cancer who had abnormal liver
biochemistry tests. Differences in prescribing habits between
clinical and medical oncologists were also investigated.
MATERIALS AND METHODS
UK consultant oncologists, identified principally from the
Directory of Cancer Specialists (1996), were invited to reply to a
postal questionnaire describing the following clinical situation:
'A woman of50 with early breast cancer was initially treated by
conservation surgery with radiotherapy and adjuvant CMF. Three
years later she had a cutaneous relapse and was started on tamox-
ifen. Six months later she developed abdominal pain and was
found to have liver metastases on ultrasound scan. Currently she
remains quite active and has no evidence of bone metastases but
her appetite is reduced.'
The oncologists were told that the aim of the survey was to
establish the patterns of anthracycline use in patients with liver
metastases and abnormal liver tests. They were also informed that
it would be used to establish whether there is a need for new dose
recommendations in these patients. The oncologists were asked
the dose (as a percentage of full dose) and choice of anthracycline
(doxorubicin, epirubicin or either) that they would prescribe for a
woman with each of the following four patterns of aspartate
aminotransferase (AST, reference range 10-35 IU 1-'), bilirubin
(3-18 gM 1-') and alkaline phosphatase (70-260 IU 1-'):
(1) AST 166, bilirubin 12, alkaline phosphatase 739;
(2) AST 132, bilirubin 30, alkaline phosphatase 190;
(3) AST 87, bilirubin 16, alkaline phosphatase 186;
(4) AST 115, bilirubin 54, alkaline phosphatase 169.
The oncologists indicated their designation as clinical (prescribing
both radiotherapy and chemotherapy) or medical (specialist
chemotherapy) oncologists.
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In an earlier pilot study of 26 oncologists, 18 (70%) replied and
the pattern of responses suggested that the questionnaire had been
understood. The pilot data are not included in the current report.
RESULTS
A total of 173 questionnaires were returned completed (63%
response rate). The dose ofanthracycline that oncologists said they
would prescribe, expressed as a percentage of full-dose treatment
for each of the four clinical situations, is shown in Figure 1A-D.
Also shown are the doses of doxorubicin and epirubicin recom-
mended in the data sheet for each of the four clinical situations.
These recommend that dosages be reduced to 50% if the serum
bilirubin is 1.2-3 mg 100 ml-' (20-50 g1M 1-1) or BSP retention is
9-15%. If serum bilirubin is greater than 3 mg per 100 ml
(50gtM 1-1) or BSP retention greater than 15%, a dose reduction
to 25% is recommended.
For each pattern of liver biochemistry some clinicians stated
that they would avoid an anthracycline altogether (question 1,
5.8%; question 2, 10.4%; question 3, 2.3%; question 4, 32.9%),
whereas others would give full-dose treatment. Twenty-six replies
specified that the anthracycline would be given at a reduced dose
on a weekly rather than a 3-weekly schedule. For patients with a
normal bilirubin but raised alkaline phosphatase and/or aspartate
aminotransferase, the current recommendation is full-dose treat-
ment. In these women, the median dose of anthracycline that
oncologists said they would prescribe was 100%. However, for a
woman with the biochemistry test values described in question 1,
only 57% ofoncologists would have prescribed this dose and 31%
would have prescribed a dose at least 25% less than that recom-
mended. Likewise, for question 3 a total of 85% of oncologists
would have prescribed an anthracycline at full dose, but 13%
would have prescribed a dose at least 25% less than recommended.
Currently, dose reductions are recommended for patients with a
raised serum bilirubin. This study confirmed that dose modifica-
tions are widely made under these circumstances. For a woman
with the raised serum bilirubin described in question 2, the median
dose prescribed was 50%. Although this is the dose that is
currently recommended, 42% of oncologists would prescribe a
dose at least 25% greater than this. Similarly, for question 4, the
median dose prescribed was 25% of that recommended; however,
a dose at least 25% greater than this would be prescribed by 14%
ofoncologists.
Table 1 compares the median dose of anthracycline that clinical
and medical oncologists said they would prescribe in each clinical
situation. A total of 97 clinical and 49 medical oncologists (84%
overall) specified their subspecialty. For each set ofliver biochem-
istry tests the anthracycline dose that would be prescribed ranged
from 0% to 100% for both the clinical and medical oncologists.
However, for the patient with the worst liver biochemistry (ques-
tion 4) the median anthracycline dose prescribed was significantly
lower for the medical than for the clinical oncologists (P = 0.04;
Mann-Whitney test). Medical oncologists were also more likely
than clinical oncologists to select weekly treatment (P = 0.02;
Fisher's exact test).
Also shown in Table I is the percentage of oncologists speci-
fying doxorubicin or epirubicin or expressing no preference. The
medical oncologists were more likely than clinical oncologists to
specify which anthracycline they would prescribe. This was prin-
cipally because of a preference for epirubicin among the medical
oncologists (P = 0.0001; Fisher's exact test). Overall, oncologists
were significantly more likely to specify epirubicin when the
serum bilirubin was raised (P < 0.0001; Fisher's exact test).
DISCUSSION
This study did not seek to identify whether clinicians would give
the 'correct' dose of an anthracycline to patients with abnormal
liver biochemistry tests. Indeed, it is not clear what constitutes
appropriate dose modifications for these patients. Rather, it sought
to establish the extent to which the current dose recommendations
are followed. The most important finding of this study is that
oncologists make widely differing anthracycline dose modifica-
tions when treating patients with liver dysfunction.
Although the anthracyclines have been used for over 20 years,
the relationship between abnormal liver biochemistry and altered
kinetics has remained unclear. Indeed, the current dose modifica-
tions have not been validated. This study shows that the uncer-
tainty regarding liver dysfunction and anthracycline kinetics is
reflected in differences in prescribing habits. Data collected from
postal surveys should be interpreted with caution (Lydeard, 1991).
As not all oncologists treat women with breast cancer, the 60%
response rate suggests that most of those for whom the question
was relevant replied. This is important as biases in postal surveys
are reduced by high response rates (Lydeard, 1991). Moreover, the
high response rate suggests that oncologists consider the question
ofanthracycline dose in patients with liver dysfunction important.
We can, therefore, be reasonably confident that the results of the
survey reflect current clinical practice in the UK.
This study shows that anthracycline doses are often reduced in
patients with abnormal liver biochemistry tests. However, these
dose modifications vary widely and often differ substantially from
those currently recommended. For each clinical scenario some
oncologists said they would avoid an anthracycline altogether,
whereas others would prescribe full-dose treatment. This vari-
ability in dosing was present in each situation but most apparent
when serum bilirubin was raised. Moreover, medical oncologists
appeared to make larger dose reductions than clinical oncologists
when liver tests were most severely disturbed. Similarly, medical
oncologists were more likely to prescribe weekly treatment or
specify the use of epirubicin. Among both medical and clinical
oncologists there was also a trend towards greater use of epiru-
bicin in the patients with a raised bilirubin. The clinical signifi-
cance of these differences is unclear. However, this variability in
prescribing habits makes it unlikely that patients with abnormal
liver biochemistry are receiving optimal treatment.
We have shown considerable variability in prescribing and that
anthracycline dose modifications often differ widely from those
currently recommended. The current modifications based princi-
pally on serum bilirubin may not be optimal (Twelves et al, 1992).
Alternative treatment strategies for patients with abnormal liver
tests based on weekly treatment (Twelves et al, 1991) and serum
AST (Dobbs et al, 1995) have been proposed. There is a need to
validate new anthracycline dose modifications in which clinicians
can have confidence.
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Figure 1 Dose of anthracycline prescribed and recommended dose (arrowed) with four abnormal patterns of liver biochemistry (n=113). (A) Question 1;
three doctors stated that they did not know what dose to give and three did not state dose. (B) Question 2 (recommended dose 100%); two doctors did not state
dose. (C) Question 3 (recommended dose 100%). (D) Question 4 (recommended dose 25%); two doctors did not state dose
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Table 1 Median anthracycline dose prescribed by clinical/medical oncologists and preferred agent
Question Per cent full dose Median per cent full Preferred drug
number recommended dose prescribed Doxorubicin/epirubicin/either
Clinical Medical (%)a
1 100 100 85 40/32/28
2 50 50 50 41/36/23
3 100 92 90 39/33/28
4b 25 50 25 40/40/20
aDifference in proportion of oncologists choosing epirubicin for questions 1 and 3 compared with questions 2 and 4 significant (P= 0.04).
bDifference between clinical and medical oncologists in dose prescribed significant (P= 0.04).
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